Calidi Biotherapeutics (NYSEAMERICAN:CLDI – Get Free Report) announced its quarterly earnings results on Thursday. The company reported ($0.43) earnings per share for the quarter, FiscalAI reports.
Calidi Biotherapeutics Price Performance
Shares of NYSEAMERICAN:CLDI traded down $0.01 on Thursday, reaching $0.19. The company’s stock had a trading volume of 3,757,766 shares, compared to its average volume of 10,506,157. The company has a 50-day simple moving average of $0.28 and a 200 day simple moving average of $0.88. Calidi Biotherapeutics has a 52-week low of $0.18 and a 52-week high of $19.20. The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.59 and a current ratio of 1.59. The company has a market cap of $2.07 million, a P/E ratio of -0.03 and a beta of 1.38.
Institutional Inflows and Outflows
A number of institutional investors have recently made changes to their positions in CLDI. Virtu Financial LLC purchased a new position in Calidi Biotherapeutics in the fourth quarter worth about $25,000. Warberg Asset Management LLC purchased a new stake in Calidi Biotherapeutics during the third quarter valued at approximately $28,000. Geode Capital Management LLC lifted its stake in shares of Calidi Biotherapeutics by 41.7% in the 4th quarter. Geode Capital Management LLC now owns 41,929 shares of the company’s stock valued at $49,000 after purchasing an additional 12,334 shares during the last quarter. Finally, DRW Securities LLC bought a new stake in shares of Calidi Biotherapeutics in the 4th quarter valued at approximately $173,000. Institutional investors own 12.53% of the company’s stock.
About Calidi Biotherapeutics
Calidi Biotherapeutics is a clinical-stage biotechnology company focused on the development of targeted immunotherapies that harness the body’s innate immune system to treat cancer and infectious diseases. By delivering proprietary RNA-based immune stimulants directly into the tumor microenvironment or sites of infection, Calidi aims to trigger a robust local immune response while minimizing systemic toxicity. The company’s platform is designed to engage multiple innate immune pathways, including toll-like receptors and RIG-I-like receptors, to initiate durable antitumor and antiviral activity.
Calidi’s lead oncology programs include CB-012, an intravesical therapy in clinical development for non-muscle invasive bladder cancer, and CB-013, an intratumoral candidate targeting a range of advanced solid tumors.
Read More
- Five stocks we like better than Calidi Biotherapeutics
- YETI Rallies After Earnings Beat and Raised Outlook
- How the 3 Leading Quantum Firms Stack Up After Q1 Earnings
- Cisco’s Vertical Rally May Still Be in the Early Innings
- Amazon vs. Alibaba: One Is Clearly The Better Value Play right Now
Receive News & Ratings for Calidi Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calidi Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
